The Regulartory Affairs Professionals Society is reporting that as part of the recently passed budget deal that the president signed Monday, generics companies whose prices rise beyond the Average Manufacturer Price that’s adjusted for inflation will have to pay higher rebates. “The amount of the rebate specified in this paragraph for a rebate period, with respect to each dosage form and strength of a covered outpatient drug other than a single source drug or an innovator multiple source drug of a manufacturer, shall be increased in the manner that the rebate for a dosage form and strength of a single source drug or an innovator multiple source drug is increased,” the act says. (RAPS)
HealthDay is reporting that researchers fromt the University of Michigan’s Survey Research Center have found that a person’s use of narcotic painkillers as a teen raises their risk of abuse as an adult by 33%. “Most likely, the initial experience of pain relief is pleasurable and a safe initial experience may reduce perceived danger,” the study’s author Richard Miech said. “A pleasurable and safe initial experience with a drug is a central factor in theories of who goes on to misuse drugs.” (HealthDay)
Some 77% of those polled by the Kaiser Family Foundation in October said that ensuring the affordability of high-cost drugs for patients with chronic conditions should be the government’s top health care priority.
Davis said that rather than support the budget deal’s Medicaid provisions, lawmakers should work to pass the Fair Access to Safe and Timely Generics Act, a bill that has been introduced by Reps. Steve Stivers, R-Ohio, and Peter Welch, D-Vt.